Močno nabit MD-2 kot antagonist LPS (Slovene)

Innate immune response to allow the human body to recognize and respond rapidly to bacterial infection. Endotoxin triggers a strong immune responses by activating monocytes and macrophages that produce several inflammatory cytokines and other inflammatory mediators. MD2, which is associated to the extracellular domain of TLR4, binds LPS and trigger cell activation. In addition to responding to bacterial infection TLR4 is involved in chronic inflammatory diseases such as atherosclerosis and others. We expect that new insights in MD2 protein stability will contribute to better understanding of MD2 agonist/antagonist recognition. This knowledge will provide the possibility to engineer better agonist and antagonist, which can be used as antiinflammatory drugs for treatment of disease such as atherosclerosis, autoimmune disease, etc. The innovative technologies and methodologies will be disseminated via presentation on conferences and publications.

The project represents an innovative methods and technologies that will be useful for scientific research as well as industry. Through lectures, laic and expert publication the knowledge will be available to experts as well as laic public. Results will be presented in international journals with impact factors, and contributions to international conferences the promotion of Slovenian country will be achieve.